Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

Renal cell carcinoma encompass distinct diseases with different pathologic features and distinct molecular pathways. Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway alone or in combination have greatly changed clinical...

Full description

Bibliographic Details
Main Authors: Solène-Florence Kammerer-Jacquet, Antoine Deleuze, Judikaël Saout, Romain Mathieu, Brigitte Laguerre, Gregory Verhoest, Frédéric Dugay, Marc-Antoine Belaud-Rotureau, Karim Bensalah, Nathalie Rioux-Leclercq
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:International Journal of Molecular Sciences
Subjects:
immunotherapy
immune checkpoint inhibition
renal cell carcinoma
PD-1
PD-L1
biomarker
tumour mutational burden
Online Access:https://www.mdpi.com/1422-0067/20/7/1692

Internet

https://www.mdpi.com/1422-0067/20/7/1692

Similar Items